197 related articles for article (PubMed ID: 30905688)
1. Pharmacology, toxicology and clinical safety of glycopyrrolate.
Chabicovsky M; Winkler S; Soeberdt M; Kilic A; Masur C; Abels C
Toxicol Appl Pharmacol; 2019 May; 370():154-169. PubMed ID: 30905688
[TBL] [Abstract][Full Text] [Related]
2. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
[TBL] [Abstract][Full Text] [Related]
3. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
[TBL] [Abstract][Full Text] [Related]
4. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M; D'Andrea P
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
[TBL] [Abstract][Full Text] [Related]
5. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
6. Use of oral glycopyrronium bromide in hyperhidrosis.
Bajaj V; Langtry JA
Br J Dermatol; 2007 Jul; 157(1):118-21. PubMed ID: 17459043
[TBL] [Abstract][Full Text] [Related]
7. Qbrexza - A glycopyrronium cloth for axillary hyperhidrosis.
Med Lett Drugs Ther; 2019 Jan; 61(1564):10-11. PubMed ID: 30856158
[No Abstract] [Full Text] [Related]
8. [Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
Ulrik CS
Ugeskr Laeger; 2013 Aug; 175(35):1946-8. PubMed ID: 23978116
[TBL] [Abstract][Full Text] [Related]
9. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
10. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Bartels C; Looby M; Sechaud R; Kaiser G
Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
[TBL] [Abstract][Full Text] [Related]
11. [New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
Yoshisue H; Kozawa M; Hiratsuka M; Nakanishi M
Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):190-9. PubMed ID: 24107524
[No Abstract] [Full Text] [Related]
12. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
13. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
14. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
15. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.
Santus P; Radovanovic D; Cristiano A; Valenti V; Rizzi M
Drug Des Devel Ther; 2017; 11():3257-3271. PubMed ID: 29180850
[TBL] [Abstract][Full Text] [Related]
16. Topical glycopyrrolate for patients with facial hyperhidrosis.
Kim WO; Kil HK; Yoon KB; Yoon DM
Br J Dermatol; 2008 May; 158(5):1094-7. PubMed ID: 18294315
[TBL] [Abstract][Full Text] [Related]
17. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Radovanovic D; Mantero M; Sferrazza Papa GF; Valenti V; Aliberti S; Di Marco F; Santus P
Expert Rev Respir Med; 2016 Oct; 10(10):1045-55. PubMed ID: 27552524
[TBL] [Abstract][Full Text] [Related]
18. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
19. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Pleasants RA
Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
[TBL] [Abstract][Full Text] [Related]
20. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate.
Luh JY; Blackwell TA
South Med J; 2002 Jul; 95(7):756-8. PubMed ID: 12144084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
